Donepezil in Treating Young Patients With Primary Brain Tumors Previously Treated With Radiation Therapy to the Brain

OBJECTIVES:

Primary

- Determine the impact of donepezil hydrochloride on cognitive function in pediatric
patients with primary brain tumors previously treated with cranial radiotherapy.

Secondary

- Assess health-related quality of life of patients treated with this drug.

- Assess function and quality of life of the families of patients treated with this drug.

- Determine the physiologic effects of radiotherapy on cerebrovascular hemodynamics in
patients treated with this drug.

- Determine the toxicity of donepezil hydrochloride in these patients.

OUTLINE: This is a multicenter, pilot, open-label, controlled study.

Patients receive oral donepezil hydrochloride once daily or once every other day for up to 24
weeks in the absence of disease progression or unacceptable toxicity. After completion of 6
weeks of study therapy, patients are evaluated for toxicity. Patients experiencing no adverse
effects from treatment may continue receiving donepezil hydrochloride at a higher dose for 18
more weeks.

Patients undergo measurement of cognitive function (by neurocognitive testing), behavioral
adjustment and social competency (by parent-reported questionnaires), health-related quality
of life (by child- and parent-reported questionnaires), and vascular dynamics (by
transcranial Doppler ultrasound) at baseline and at weeks 12, 24, and 36. Family function and
family quality of life are assessed at baseline and at week 24.

PROJECTED ACCRUAL: A total of 35 patients will be accrued for this study.

Inclusion Criteria:

- Prior diagnosis of primary brain tumor

- No type 2 neurofibromatosis

- Underwent fractionated radiotherapy (≥ 23.4 Gy) with or without surgery or
chemotherapy for the brain tumor at least 1 year ago

- Karnofsky or Lansky performance status 70-100%

- Fertile patients willing to use effective contraception

- Baseline IQ ≥ 70 on Peabody Picture Vocabulary Test-3

- Stable weight within the past 6 months with no concern of weight loss

- Vision aids and hearing aids must be used for all neuropsychologic/neurocognitive
tests, If indicated

- Able to speak English

- More than 6 weeks since prior donepezil hydrochloride, EGb761, methylphenidate
hydrochloride, other stimulants, or any other cognitive function-enhancing drug

Exclusion Criteria:

- Stereotactic radiosurgery as sole treatment

- Evidence of disease progression by MRI

- Pregnant or nursing

- Attention-deficit/hyperactivity disorder before cancer diagnosis

- Uncontrolled seizures or uncontrolled endocrinopathies

- Uncontrolled comorbidities

- Steroid dose greater than physiologic replacement (18-30 mg/m² hydrocortisone or
equivalent)

- Use of concurrent anticholinergic drugs